{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T03:04:40Z","timestamp":1772593480726,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Noninferiority trials of treatment for latent tuberculosis infection (LTBI) are challenging because of imperfect LTBI diagnostic tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effect on study outcomes of different enrollment strategies for a noninferiority trial of LTBI treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We mathematically simulated a two-arm randomized clinical trial of LTBI in which the experimental therapy was 50% efficacious and the control was 80% efficacious, with an absolute 0.75% noninferiority margin. Five enrollment strategies were assessed: 1) enroll based on no LTBI diagnostic test; 2) enroll based on a positive tuberculin skin test (TST); 3) enroll based on a positive IFN-\u03b3 release assay (IGRA); 4) enroll based on either a positive TST or IGRA; and 5) enroll regardless of test result, assuming 70% had negative TSTs, 20% positive TSTs, and 10% unknown results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Under most LTBI prevalence assumptions, enrolling based on a positive IGRA was least likely to result in falsely declaring noninferiority of the experimental regimen. Enrolling based on no test or regardless of test result led to falsely declaring noninferiority unless LTBI prevalence in the underlying population was higher than 45%. Enrolling based on a mix of TST and IGRA substantially reduced the likelihood of falsely declaring noninferiority over enrolling based on TST alone, even if as many as 70% of participants were enrolled based on positive TST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Noninferiority trials of LTBI should enroll based on the most specific diagnostic tests available (i.e., IGRAs) to avoid misclassifying inferior treatment regimens as noninferior.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201908-1606oc","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T22:54:07Z","timestamp":1573512847000},"page":"598-605","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":7,"title":["Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling"],"prefix":"10.1093","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6698-8176","authenticated-orcid":false,"given":"Jason E.","family":"Stout","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0650-4894","authenticated-orcid":false,"given":"Nicholas A.","family":"Turner","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7382-8592","authenticated-orcid":false,"given":"Robert W.","family":"Belknap","sequence":"additional","affiliation":[{"name":"Denver Health and Hospital Authority and Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-7895","authenticated-orcid":false,"given":"C. Robert","family":"Horsburgh","sequence":"additional","affiliation":[{"name":"Departments of Epidemiology, Biostatistics, Global Health, and Medicine, Boston University Schools of Public Health and Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4822-6979","authenticated-orcid":false,"given":"Timothy R.","family":"Sterling","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7024","authenticated-orcid":false,"given":"Patrick P. J.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Medicine, UCSF Center for Tuberculosis, University of California\u2013San Francisco, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,3,1]]},"reference":[{"key":"2026030321421462400_bib1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026030321421462400_bib2","doi-asserted-by":"crossref","first-page":"e0142290","DOI":"10.1371\/journal.pone.0142290","article-title":"Isoniazid prophylactic therapy for the prevention of tuberculosis in HIV infected adults: a systematic review and meta-analysis of randomized trials","volume":"10","author":"Ayele","year":"2015","journal-title":"PLoS One"},{"key":"2026030321421462400_bib3","first-page":"CD000171","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","author":"Akolo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026030321421462400_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"2026030321421462400_bib5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/520983","article-title":"The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study","volume":"45","author":"Spyridis","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026030321421462400_bib6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2026030321421462400_bib7","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026030321421462400_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","article-title":"Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update","volume":"149","author":"Pai","year":"2008","journal-title":"Ann Intern Med"},{"key":"2026030321421462400_bib9","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1473-3099(18)30355-4","article-title":"Prognostic value of interferon-\u03b3 release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study","volume":"18","author":"Abubakar","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026030321421462400_bib10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/thoraxjnl-2018-211715","article-title":"Evaluating latent tuberculosis infection diagnostics using latent class analysis","volume":"73","author":"Stout","year":"2018","journal-title":"Thorax"},{"key":"2026030321421462400_bib11","doi-asserted-by":"crossref","first-page":"e17984","DOI":"10.1371\/journal.pone.0017984","article-title":"The tuberculin skin test versus QuantiFERON TB Gold in predicting tuberculosis disease in an adolescent cohort study in South Africa","volume":"6","author":"Mahomed","year":"2011","journal-title":"PLoS One"},{"key":"2026030321421462400_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","article-title":"Predictive value of interferon-\u03b3 release assays for incident active tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Rangaka","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2026030321421462400_bib13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2026030321421462400_bib14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"Danel","year":"2015","journal-title":"N Engl J Med"},{"key":"2026030321421462400_bib15","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1016\/S2214-109X(17)30372-8","article-title":"Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial","volume":"5","author":"Badje","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2026030321421462400_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","article-title":"Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial","volume":"384","author":"Rangaka","year":"2014","journal-title":"Lancet"},{"key":"2026030321421462400_bib17","doi-asserted-by":"crossref","first-page":"e22276","DOI":"10.1371\/journal.pone.0022276","article-title":"Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection","volume":"6","author":"Holland","year":"2011","journal-title":"PLoS One"},{"key":"2026030321421462400_bib18","author":"Department of Health and Human Services FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research"},{"key":"2026030321421462400_bib19","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management.","author":"Global Tuberculosis Programme","year":"2018"},{"key":"2026030321421462400_bib20","doi-asserted-by":"crossref","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"key":"2026030321421462400_bib21","doi-asserted-by":"crossref","first-page":"e0140881","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011-2012","volume":"10","author":"Miramontes","year":"2015","journal-title":"PLoS One"},{"key":"2026030321421462400_bib22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1164\/rccm.201508-1683OC","article-title":"The prevalence of latent tuberculosis infection in the United States","volume":"194","author":"Mancuso","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321421462400_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1164\/rccm.201508-1560OC","article-title":"Latent tuberculosis infection test agreement in the National Health and Nutrition Examination Survey","volume":"194","author":"Ghassemieh","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321421462400_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12879-015-0904-1","article-title":"Prevalence of latent tuberculosis infection and associated risk factors in an urban African setting","volume":"15","author":"Kizza","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2026030321421462400_bib25","article-title":"Estimating the prevalence of latent tuberculosis in a low-incidence setting: Australia","volume":"52:1801218","author":"Dale","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030321421462400_bib26","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.2105\/AJPH.2018.304687","article-title":"Age-period-cohort analyses of tuberculosis incidence rates by nativity, United States, 1996-2016","volume":"108","author":"Iqbal","year":"2018","journal-title":"Am J Public Health"},{"key":"2026030321421462400_bib27","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1086\/314075","article-title":"What does tuberculin reactivity after bacille Calmette-Gu\u00e9rin vaccination tell us?","volume":"31","author":"Menzies","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2026030321421462400_bib28","first-page":"1192","article-title":"False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?","volume":"10","author":"Farhat","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026030321421462400_bib29","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/thoraxjnl-2015-207687","article-title":"The impact of BCG vaccination on tuberculin skin test responses in children is age dependent: evidence to be considered when screening children for tuberculosis infection","volume":"71","author":"Seddon","year":"2016","journal-title":"Thorax"},{"key":"2026030321421462400_bib30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1164\/rccm.201406-1159OC","article-title":"Risk of tuberculosis after recent exposure: a 10-year follow-up study of contacts in Amsterdam","volume":"190","author":"Sloot","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321421462400_bib31","article-title":"Risk factors for tuberculosis and effect of preventive therapy among close contacts of persons with infectious tuberculosis","author":"Reichler","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026030321421462400_bib32","first-page":"780","article-title":"How much isoniazid is needed for prophylaxis?","volume":"101","author":"Comstock","year":"1970","journal-title":"Am Rev Respir Dis"}],"updated-by":[{"DOI":"10.1164\/rccm.v206erratum8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000}}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/201\/5\/598\/67181488\/ajrccm_201_5_598.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/201\/5\/598\/67181488\/ajrccm_201_5_598.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:42:21Z","timestamp":1772592141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/201\/5\/598\/8496459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,3,1]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201908-1606oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2020,3,1]]},"assertion":[{"value":"2019-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}